Japanese Korean Chinese Simplified Chinese Traditional 

Conference Menu

Current Event 

Day 1
Day 2
Day 3
PDF Download
Short Course
Hotel & Travel 
Sponsorship & Exhibits
Press Pass 
Request Brochure 

Corporate Sponsors

Blue Sky Bioservices


EMD Millipore

Parthys Reverse Informatics 

Promega BLACK 

Lead Sponsoring Publications


Science AAAS 


Sponsoring Publications


The Scientist 

Media Partner



Web Partner




Novel Examples of Non-ATP Site Inhibitors

Doriano Fabbro, Ph.D., Executive Director, Expertise Kinase Platforrm, CPC, Novartis Pharma AG

Comprehensive Assay of Kinase Catalytic Activity Reveals Features of Kinase Inhibitor Selectivity and Novel Kinase-Inhibitor Interactions

Jeffrey R. Petersen, Ph.D., Associate Professor, Cancer Genetics and Signaling, Fox Chase Cancer Center

Activation-State Dependent Conformational Differences in Protein Kinases and the Role of Hydrophobic Motifs in Inactive Kinases: Lessons Learned in Drug Discovery and Optimization

Mark Ashwell, Ph.D., Vice President, Chemistry, ArQule

Development of a Mono-Selective CDK7 Inhibitor Lead

Jan Eickhoff, Ph.D., Head of Assay Development and Screening, Lead Discovery, Centrum GmBH

Targeting the Unfolded Protein Response: Discovery and Characterization of Selective First-in-Class PERK Inhibitors

Jeffrey M. Axten, Ph.D., Director, Medicinal Chemistry, Protein Dynamics DPU, Oncology Business Unit, GlaxoSmithKline

Multiple Strategies for Overcoming Kinase Inhibitor Resistance

Nathanael S. Gray, Ph.D., Assistant Professor, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School 

Pathway-Based Identification of Biomarkers for Targeted Kinase Therapeutics

An Chi, Ph.D., Research Fellow, Molecular Biomarkers Department, Merck Research Laboratory

Aptamers: A New Class of Tyrosine Kinase Inhibitors

Said Ismail, Ph.D., Associate Professor, Molecular Biology, Department of Biochemistry, Medical School, University of Jordan

Development and Activity of Inhibitors of the Atypical Mitotic Kinase Haspin

Jonathan Higgins, Ph.D., Assistant Professor, Medicine, Brigham & Women’s Hospital, Harvard Medical School

Kinase Virtual Screening with Accuracy Comparable to Experiment

Eric Martin, Ph.D., Director, Computational Chemistry, Global Discovery Chemistry, Novartis institutes for BioMedical Research

Structure-Guided Design of Biologically Active and Highly Selective Inhibitors of the CK1 Family of Protein Kinases for the Treatment of Cancer, Inflammation and Neurological Disorders

Jeffrey F. Ohren, Ph.D., CSO, Emil's Molecular Design, LLC; Senior Research Specialist, Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor

Talk Title to be Announced

Milton H. Werner, Ph.D., President & CEO, Inhibikase Therapeutics, Inc.

Resistance of Akt Kinases to Dephosphorylation through ATP-Dependent Conformational Plasticity

Roger S. Armen, Ph.D., Assistant Professor of Medicinal Chemistry, Department of Pharmaceutical Sciences, Thomas Jefferson University, School of Pharmacy

Integrate Structural, Biophysical and Computational Methods to Understand Glucokinase Function and Design Novel Allosteric Activators

Xiayang Qiu, Ph.D., Senior Director, Head of Structure Biology & Biophysics, Pfizer, Inc.

Identification of DYG-out Inhibitors of LRRK2 Based on Structural Modeling and Enzyme Kinetic Studies

Min Liu, Ph.D., Assistant Director, The Laboratory of Drug Discovery for Neurodegeneration, LDDN, Harvard NeuroDiscovery Center, HNDC, Brigham and Women’s Hospital

Determining the Crystal Structures of Allosteric Kinase Inhibitor Complexes

Barbara Brandhuber, Ph.D., Director, Early Drug Discovery, Biology, Array BioPharma

Inhibiting PI3K for Treating Inflammatory Diseases

Stephen J. Shuttleworth, Ph.D., CSO, Karus Therapeutics, Ltd.

Developing Novel Drak2 Inhibitors for the Treatment of Autoimmune Diseases

Jiangping Wu, Ph.D., Professor of Medicine, Medicine, University of Montreal

Druggability and Ligandability: Structural Genomics Insights Suggest in Excess Of 10,000 Potentially Druggable Proteins in the Human Proteome

Florian Nigsch, Ph.D., Presidential Postdoctoral Fellow, Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research

Integrate Structural, Biophysical and Computational Methods to Understand Glucokinase Function and Design Novel Allosteric Activators

Xiayang Qiu, Ph.D., Senior Director, Head of Structure Biology & Biophysics, Pfizer, Inc.

Discovery of Potent, Selective, and Orally Bioavailable SIK2 Kinase Inhibitors for Multiple Disease Indications

Hariprasad Vankayalapati, Ph.D., Scientific Advisor, Arrien Pharmaceuticals

Identification of Novel Non ATP – Competitive Inhibitors against Human MAP Kinase Kinase1 (MEK1) and MEK2

Rambabu Gundla, Ph.D., Principal Scientist, Informatics, GVKBIO Sciences Pvt Ltd.